Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 386

1.

Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J.

BMC Neurol. 2016 Apr 16;16:48. doi: 10.1186/s12883-016-0568-5.

2.

Epileptic syndrome in systemic lupus erythematosus and neuronal autoantibody associations.

Kampylafka EI, Alexopoulos H, Fouka P, Moutsopoulos HM, Dalakas MC, Tzioufas AG.

Lupus. 2016 Feb 27. pii: 0961203316636473. [Epub ahead of print]

PMID:
26923281
3.

Close to the node but far enough: What nodal antibodies tell us about CIDP and its therapies.

Dalakas MC, Gooch C.

Neurology. 2016 Mar 1;86(9):796-7. doi: 10.1212/WNL.0000000000002427. Epub 2016 Feb 3. No abstract available.

PMID:
26843563
4.

Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab.

Magira EE, Alexopoulos H, Charitatos E, Michas D, Dalakas MC.

Ther Adv Neurol Disord. 2016 Jan;9(1):69-73. doi: 10.1177/1756285615614812. No abstract available.

5.

Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.

Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):1-3. doi: 10.1007/s13311-015-0414-2. No abstract available.

PMID:
26684870
6.

Viruses in IBM: Hit-and-run, hide and persist, or irrelevant?

Dalakas MC, Schmidt J.

Neurology. 2016 Jan 19;86(3):204-5. doi: 10.1212/WNL.0000000000002295. Epub 2015 Dec 18. No abstract available.

PMID:
26683647
7.

Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease.

Alexopoulos H, Kampylafka EI, Fouka P, Tatouli I, Akrivou S, Politis PK, Moutsopoulos HM, Tzioufas AG, Dalakas MC.

J Neuroimmunol. 2015 Dec 15;289:8-11. doi: 10.1016/j.jneuroim.2015.10.007. Epub 2015 Oct 13.

PMID:
26616866
8.

Future perspectives in target-specific immunotherapies of myasthenia gravis.

Dalakas MC.

Ther Adv Neurol Disord. 2015 Nov;8(6):316-27. doi: 10.1177/1756285615605700. Review.

9.

Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Alexopoulos H, Biba A, Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):20-33. doi: 10.1007/s13311-015-0402-6.

PMID:
26566961
10.

Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Kampylafka EI, Alexopoulos H, Dalakas MC, Tzioufas AG.

Neurotherapeutics. 2016 Jan;13(1):163-78. doi: 10.1007/s13311-015-0393-3.

PMID:
26510559
11.

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.

Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD.

J Clin Invest. 2015 Nov 2;125(11):4160-70. doi: 10.1172/JCI82695. Epub 2015 Oct 5.

12.

Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Lünemann JD, Quast I, Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):34-46. doi: 10.1007/s13311-015-0391-5.

PMID:
26400261
13.

Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4.

Kampylafka EI, Alexopoulos H, El Hamidieh A, Dalakas MC, Andreakos E, Tzioufas AG.

Autoimmunity. 2015;48(7):453-9. doi: 10.3109/08916934.2015.1070836. Epub 2015 Aug 14.

PMID:
26287441
14.

Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4.

Kampylafka EI, Alexopoulos H, El Hamidieh A, Dalakas MC, Andreakos E, Tzioufas AG.

Autoimmunity. 2015 Aug 14:1-7. [Epub ahead of print]

PMID:
26275078
15.

Inflammatory Muscle Diseases.

Dalakas MC.

N Engl J Med. 2015 Jul 23;373(4):393-4. doi: 10.1056/NEJMc1506827. No abstract available.

16.

Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis.

Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 2;2(4):e131. doi: 10.1212/NXI.0000000000000131. eCollection 2015 Aug. No abstract available.

17.

HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis.

Muth IE, Zschüntzsch J, Kleinschnitz K, Wrede A, Gerhardt E, Balcarek P, Schreiber-Katz O, Zierz S, Dalakas MC, Voll RE, Schmidt J.

Exp Neurol. 2015 Sep;271:189-97. doi: 10.1016/j.expneurol.2015.05.023. Epub 2015 Jun 3.

PMID:
26048613
18.

Inflammatory muscle diseases.

Dalakas MC.

N Engl J Med. 2015 Apr 30;372(18):1734-47. doi: 10.1056/NEJMra1402225. Review. No abstract available.

PMID:
25923553
19.

GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders.

Fouka P, Alexopoulos H, Akrivou S, Trohatou O, Politis PK, Dalakas MC.

J Neuroimmunol. 2015 Apr 15;281:73-7. doi: 10.1016/j.jneuroim.2015.03.009. Epub 2015 Mar 10.

PMID:
25867471
20.

Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.

Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, Van Doorn PA, Dalakas MC, Latov N.

Muscle Nerve. 2015 Oct;52(4):498-502. doi: 10.1002/mus.24624. Epub 2015 Jul 24.

PMID:
25728021
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk